Cellectis (CLLS) EPS (Basic) (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.87% |
| Dec 31, 2025 | -670.12% |
| Sep 30, 2025 | 87.49% |
| Jun 30, 2025 | 356.94% |
| Mar 31, 2025 | 93.03% |
| Dec 31, 2024 | -1,318.06% |
| Dec 31, 2023 | -119.35% |
| Sep 30, 2023 | -55.00% |
| Jun 30, 2023 | -14,766.77% |
| Mar 31, 2023 | 97.88% |
| Dec 31, 2022 | -3,168.19% |
| Sep 30, 2022 | -19,858.65% |
| Jun 30, 2022 | 99.56% |
| Mar 31, 2022 | 98.77% |
| Dec 31, 2021 | -1,134.15% |
| Sep 30, 2021 | -13.08% |
| Jun 30, 2021 | -78.95% |
| Mar 31, 2021 | 99.22% |
| Dec 31, 2020 | -8,532.92% |
| Sep 30, 2020 | 11.13% |
| Jun 30, 2020 | -329.11% |
| Mar 31, 2020 | 100.57% |
| Dec 31, 2019 | -9,308.17% |
| Sep 30, 2019 | 24.13% |
| Jun 30, 2019 | -51.88% |
| Mar 31, 2019 | 98.79% |
| Dec 31, 2018 | -6,497.99% |
| Sep 30, 2018 | -33.17% |
| Jun 30, 2018 | 25.17% |
| Mar 31, 2018 | 98.64% |
| Dec 31, 2017 | -7,003.59% |
| Sep 30, 2017 | 1.76% |
| Jun 30, 2017 | 1.07% |
| Mar 31, 2017 | 97.90% |
| Dec 31, 2016 | -7,197.93% |
| Sep 30, 2016 | -28.74% |
| Jun 30, 2016 | 51.08% |